Meperidine for patients expected to have poor tolerance to esophagogastroduodenoscopy: A double

Anxious patients and those with poor tolerance to previous esophagogastroduodenoscopy (EGD) usually have poor tolerance for EGD. To investigate the effect of meperidine on these patients during EGD. A total of 110 patients undergoing diagnostic EGD were randomized to receive either meperidine (n？=？55) or placebo (n？=？55) before EGD. The primary outcome was patient discomfort scores during esophageal intubation. Patients in the meperidine group reported less discomfort during esophageal intubation (median score of 5.0 and interquartile range (IQR) 1.5–7.0) compared with the control (median score of 6.0, IQR 5.0–8.5, P？=？.003). Patients in the meperidine group had better tolerance during the procedure (median score of 2 (IQR 1.0–3.0) versus 3 (IQR 1.0–4.0), P？=？.048), and the endoscopists reported higher overall satisfaction scores (median score of 9 (IQR 7.0–9.0) versus 8 (IQR 7.0–9.0), P？=？.043). There was significantly less increase in heart rate and blood pressure during the procedure in the meperidine group than in the placebo group (23 bpm (IQR 9–32) versus 30 bpm (IQR 18–52); P？=？.006); (7？mmHg (IQR 1–14) versus 18？mmHg (IQR 2–30); P？=？.008). Connect-the-numbers test showed comparable results before and after EGD between the two groups. For patients expected to have poor tolerance during EGD, meperidine reduced discomfort, decreased cardiovascular distress, and improved endoscopist satisfaction, without adverse effects on their psychomotor function after the procedure